• Optimizing Platelet Production from hiPSCs: Src Inhibition A

  2026-05-19

  This study presents a systematically optimized protocol for differentiating functional platelets from human induced pluripotent stem cells (hiPSCs), leveraging small molecule modulation—including Src tyrosine kinases inhibition—to enhance yield, efficiency, and cost-effectiveness. The findings offer scalable solutions for ex vivo platelet manufacturing and highlight practical advances for regenerative medicine.

• Angiotensin 1/2 (2-7): Mechanisms and Benchmarks in RAS Rese

  2026-05-19

  Angiotensin 1/2 (2-7) is a bioactive vasoconstrictor peptide critical for blood pressure regulation research. Its defined sequence and cleavage profile make it a precise tool for dissecting renin-angiotensin system mechanisms, with well-characterized solubility and stability parameters.

• ECL Chemiluminescent Substrate Detection Kit: Mechanisms & B

  2026-05-18

  The ECL Chemiluminescent Substrate Detection Kit from APExBIO enables ultrasensitive detection of HRP-labeled antibodies in Western blot chemiluminescence detection. Its luminol-based system achieves low-picogram protein visualization with high signal-to-noise, making it a core tool for chemiluminescent immunoassays and protein detection by ECL.

• PPZ1-TORC1 Pathway Regulates Ferroptosis and Drug Resistance

  2026-05-18

  This study uncovers a fungus-specific regulatory axis, the PPZ1-TORC1 pathway, that modulates ferroptosis and antifungal resistance in Candida albicans. By linking autophagy, lipid peroxidation, and iron-dependent cell death, the findings offer a mechanistic basis for novel antifungal strategies targeting ferroptosis.

• Honokiol in Quantitative In Vitro Drug Response: A Systems P

  2026-05-17

  Explore how Honokiol, a potent NF-κB pathway inhibitor and antioxidant, enables more nuanced, quantitative assessment of drug responses in cancer research. This article uniquely integrates insights from systems biology and in vitro assay methodology to guide advanced experimental design.

• Angiotensin II (A1042): Mechanistic Insights & Research Use

  2026-05-16

  Angiotensin II is a potent vasopressor and GPCR agonist used to model hypertension and vascular remodeling. Its mechanism involves receptor-mediated signaling and aldosterone induction, critical for fluid balance and cardiovascular research. This article details verifiable applications and experimental parameters for Angiotensin II (A1042).

• SB 431542: ALK5 Inhibitor Workflows for TGF-β Pathway Dissec

  2026-05-15

  SB 431542 stands out as a gold-standard ALK5 inhibitor for precise TGF-β pathway manipulation in stem cell and cancer research. This guide translates recent organoid modeling advances and benchmarked protocols into actionable workflows, optimizing selectivity and reproducibility for developmental biology and anti-tumor assays.

• Cisapride in Predictive Cardiac Electrophysiology: Beyond hE

  2026-05-15

  Explore how Cisapride (R 51619) empowers next-generation cardiac electrophysiology research, illuminating serotonergic pathways and hERG channel inhibition. This article uniquely analyzes deep learning-enabled phenotypic screening and practical assay optimization for advanced cardiotoxicity modeling.

• Honokiol in Cancer Research: Applied Workflows & Troubleshoo

  2026-05-14

  Honokiol, a bioactive NF-κB pathway inhibitor, enables precise modulation of inflammatory and oxidative signaling in advanced cancer biology workflows. Explore optimized protocols, troubleshooting strategies, and evidence-based insights that set it apart as a research-use antioxidant and antiangiogenic compound. APExBIO’s high-purity Honokiol supports reproducible, robust in vitro and translational studies.

• Empowering Lipid Droplet Research: Protease Inhibitors in Ac

  2026-05-14

  Explore how mechanistic insights into DFCP1-ATGL regulation and strategic use of advanced protease inhibitor mixtures transform translational lipid metabolism research. This thought-leadership article bridges cutting-edge discovery with practical workflow guidance, revealing how robust protein stability enhancers like APExBIO’s Protease Inhibitor Cocktail (100X H₂O, EDTA Plus) safeguard labile complexes, elevate data quality, and pave the way for new metabolic disease interventions.

• CFDA SE Cell Tracer Kit: Technical Parameters and Best Pract

  2026-05-13

  The CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Cell Tracer Kit provides durable, covalent fluorescent labeling for precise cell tracking and proliferation studies, both in vitro and in vivo. This kit is optimized for workflows requiring stable, long-term cell tracing, but is not suitable for reversible or short-term labeling tasks.

• Angiotensin (1-7): Protocols and Innovation for Translationa

  2026-05-13

  Angiotensin (1-7) enables precise modulation of anti-fibrotic, anti-inflammatory, and metabolic pathways through Mas receptor signaling, making it invaluable for both disease mechanism studies and therapeutic innovation. This guide delivers actionable workflows, troubleshooting insights, and fresh perspectives on leveraging APExBIO's high-purity Angiotensin (1-7) peptide across diverse research domains.

• Tropisetron Hydrochloride: Precision Tools for 5-HT3 Signali

  2026-05-12

  Explore the unique dual action of Tropisetron Hydrochloride as a 5-HT3 receptor antagonist and α7-nicotinic receptor agonist. This in-depth guide offers advanced insights into its use for dissecting serotonin receptor signaling pathways in neuroscience, with a special focus on renal transporter interactions and practical assay implications.

• Honokiol as a Quantitative Tool: Redefining In Vitro Drug Re

  2026-05-12

  Discover how Honokiol, a bioactive small molecule, is uniquely positioned to advance quantitative in vitro drug response studies. This article explores its mechanistic depth and distinct advantages for assay precision and translational cancer research.

• BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guidan

  2026-05-11

  BFH772 is a highly selective VEGFR2 inhibitor designed for research applications targeting VEGFR2-mediated angiogenesis, particularly in tumor models. It should not be used in workflows requiring water solubility or broad-spectrum kinase inhibition due to its defined selectivity and solubility profile.

695 records 13/47 page Previous Next First page 上5页 1112131415 下5页 Last page